Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced its quarterly earnings data on Monday. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.02), Bloomberg Earnings reports. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.79 EPS.

Zimmer Biomet Holdings (ZBH) traded down 4.48% on Wednesday, hitting $116.17. 2,680,500 shares of the stock were exchanged. Zimmer Biomet Holdings has a 1-year low of $95.63 and a 1-year high of $133.49. The company’s 50 day moving average is $118.31 and its 200 day moving average is $120.47. The stock has a market cap of $23.49 billion, a PE ratio of 33.09 and a beta of 1.19.

The firm also recently declared a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 22nd were given a $0.24 dividend. The ex-dividend date of this dividend was Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet Holdings’s payout ratio is currently 27.59%.

COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://theolympiareport.com/2017/11/01/zimmer-biomet-holdings-inc-zbh-releases-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.

Several equities analysts recently commented on ZBH shares. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. BMO Capital Markets reaffirmed a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Wells Fargo & Company reaffirmed a “market weight” rating on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Morgan Stanley upped their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday, July 17th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $125.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $136.55.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.